Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorDANILOVIC, Debora L. S.
dc.contributor.authorCASTRO JR., Gilberto
dc.contributor.authorROITBERG, Felipe S. R.
dc.contributor.authorVANDERLEI, Felipe A. B.
dc.contributor.authorBONANI, Fernanda A.
dc.contributor.authorFREITAS, Ricardo M. C.
dc.contributor.authorCOURA-FILHO, George B.
dc.contributor.authorCAMARGO, Rosalinda Y.
dc.contributor.authorKULCSAR, Marco A.
dc.contributor.authorMARUI, Suemi
dc.contributor.authorHOFF, Ana O.
dc.date.accessioned2018-09-13T15:27:24Z
dc.date.available2018-09-13T15:27:24Z
dc.date.issued2018
dc.description.abstractTotal thyroidectomy, radioiodine (RAI) therapy, and TSH suppression are the mainstay treatment for differentiated thyroid carcinomas (DTCs). Treatments for metastatic disease include surgery, external-beam radiotherapy, RAI, and kinase inhibitors for progressive iodine-refractory disease. Unresectable locoregional disease remains a challenge, as standard therapy with RAI becomes unfeasible. We report a case of a young patient who presented with unresectable papillary thyroid carcinoma (PTC), and treatment with sorafenib allowed total thyroidectomy and RAI therapy. A 20-year-old male presented with severe respiratory distress due to an enlarging cervical mass. Imaging studies revealed an enlarged multinodular thyroid gland, extensive cervical adenopathy, severe tracheal stenosis, and pulmonary micronodules. He required an urgent surgical intervention and underwent tracheostomy and partial left neck dissection, as the disease was deemed unresectable; pathology revealed PTC. Treatment with sorafenib was initiated, resulting in significant tumor reduction allowing near total thyroidectomy and bilateral neck dissection. Postoperatively, the patient underwent radiotherapy for residual tracheal lesion, followed by RAI therapy for avid cervical and pulmonary disease. The patient's disease remains stable 4 years after diagnosis. Sorafenib has been approved for progressive RAI-refractory metastatic DTCs. In this case report, we describe a patient with locally advanced PTC in whom treatment with sorafenib provided sufficient tumor reduction to allow thyroidectomy and RAI therapy, suggesting a potential role of sorafenib as an induction therapy of unresectable DTC.
dc.description.indexMEDLINE
dc.description.sponsorshipAstra Zeneca
dc.description.sponsorshipEisai
dc.description.sponsorshipBayer
dc.description.sponsorshipAstraZeneca
dc.description.sponsorshipExelixis
dc.description.sponsorshipGenzyme
dc.identifier.citationARCHIVES OF ENDOCRINOLOGY METABOLISM, v.62, n.3, p.370-375, 2018
dc.identifier.doi10.20945/2359-3997000000046
dc.identifier.eissn2359-4292
dc.identifier.issn2359-3997
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/28312
dc.language.isoeng
dc.publisherSBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA
dc.relation.ispartofArchives of Endocrinology Metabolism
dc.rightsopenAccess
dc.rights.holderCopyright SBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA
dc.subject.otherrenal-cell carcinoma
dc.subject.otherradioactive iodine
dc.subject.otherstaging system
dc.subject.otherclinical-trial
dc.subject.otherchemotherapy
dc.subject.othermanagement
dc.subject.otherphase-2
dc.subject.otheredition
dc.subject.otherage
dc.subject.wosEndocrinology & Metabolism
dc.titlePotential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus17
hcfmusp.contributor.author-fmusphcDEBORA LUCIA SEGURO DANILOVIC
hcfmusp.contributor.author-fmusphcGILBERTO DE CASTRO JUNIOR
hcfmusp.contributor.author-fmusphcFELIPE SANTA ROSA ROITBERG
hcfmusp.contributor.author-fmusphcFELIPE AUGUSTO BRASILEIRO VANDERLEI
hcfmusp.contributor.author-fmusphcFERNANDA AMARANTE BONANI
hcfmusp.contributor.author-fmusphcRICARDO MIGUEL COSTA DE FREITAS
hcfmusp.contributor.author-fmusphcGEORGE BARBERIO COURA FILHO
hcfmusp.contributor.author-fmusphcROSALINDA YOSSIE ASATO DE CAMARGO
hcfmusp.contributor.author-fmusphcMARCO AURELIO VAMONDES KULCSAR
hcfmusp.contributor.author-fmusphcSUEMI MARUI
hcfmusp.contributor.author-fmusphcANA AMELIA FIALHO DE OLIVEIRA HOFF
hcfmusp.description.beginpage370
hcfmusp.description.endpage375
hcfmusp.description.issue3
hcfmusp.description.volume62
hcfmusp.origemWOS
hcfmusp.origem.pubmed29791660
hcfmusp.origem.scieloSCIELO:S2359-39972018000300370
hcfmusp.origem.scopus2-s2.0-85050716251
hcfmusp.origem.wosWOS:000437084400016
hcfmusp.publisher.cityRIO DE JANEIRO, RJ
hcfmusp.publisher.countryBRAZIL
hcfmusp.relation.referenceArk N, 2008, SURG ONCOL CLIN N AM, V17, P145, DOI 10.1016/j.soc.2007.10.009
hcfmusp.relation.referenceBarbier L, 2011, INT J HEPATOL, DOI 10.4061/2011/791013
hcfmusp.relation.referenceBesic N, 2013, THYROID, V23, P178, DOI 10.1089/thy.2012.0194
hcfmusp.relation.referenceBesic N, 2012, THYROID, V22, P131, DOI 10.1089/thy.2011.0243
hcfmusp.relation.referenceBorregales LD, 2016, THER ADV UROL, V8, P130, DOI 10.1177/1756287215612962
hcfmusp.relation.referenceBrose MS, 2016, LANCET ONCOL, V17, P1272, DOI 10.1016/S1470-2045(16)30166-8
hcfmusp.relation.referenceBrose MS, 2014, LANCET, V384, P319, DOI 10.1016/S0140-6736(14)60421-9
hcfmusp.relation.referenceCleary JM, 2010, J CLIN ONCOL, V28, pE390, DOI 10.1200/JCO.2009.27.4225
hcfmusp.relation.referenceCowey CL, 2010, J CLIN ONCOL, V28, P1502, DOI 10.1200/JCO.2009.24.7759
hcfmusp.relation.referenceDang RP, 2016, INT J SURG ONCOL, V2016
hcfmusp.relation.referenceHoftijzer H, 2009, EUR J ENDOCRINOL, V161, P923, DOI 10.1530/EJE-09-0702
hcfmusp.relation.referenceIto Y, 2012, ENDOCR J, V59, P839, DOI 10.1507/endocrj.EJ12-0174
hcfmusp.relation.referenceKiess AP, 2016, HEAD NECK-J SCI SPEC, V38, P493, DOI 10.1002/hed.24357
hcfmusp.relation.referenceLoibl S, 2014, BREAST CARE, V9, P169, DOI 10.1159/000363430
hcfmusp.relation.referenceNixon IJ, 2016, THYROID, V26, P373, DOI 10.1089/thy.2015.0315
hcfmusp.relation.referenceOrosco RK, 2015, THYROID, V25, P125, DOI 10.1089/thy.2014.0116
hcfmusp.relation.referenceSchlumberger M, 2014, J CLIN ONCOL, V32
hcfmusp.relation.referenceSchlumberger M, 2015, NEW ENGL J MED, V372, P621, DOI 10.1056/NEJMoa1406470
hcfmusp.relation.referenceShah DR, 2014, DRUG SAFETY, V37, P135, DOI 10.1007/s40264-014-0139-x
hcfmusp.relation.referenceTuttle RM, 2017, THYROID, V27, P751, DOI 10.1089/thy.2017.0102
hcfmusp.relation.referenceWada N, 2007, J CLIN ENDOCR METAB, V92, P215, DOI 10.1210/jc.2006-1443
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication7574dcd5-619b-44d8-9f24-a0358bb965ce
relation.isAuthorOfPublication0df25c0f-1337-424e-b0f7-41d0fccb51fc
relation.isAuthorOfPublication11dd934a-f8bb-43f3-986c-0f7a35be411d
relation.isAuthorOfPublication22c6c954-dc6c-4e5a-8939-2af02e9f3705
relation.isAuthorOfPublicationf666741e-7b81-4691-81d6-a2a48d892554
relation.isAuthorOfPublication78e4e7e7-37f1-4e41-8db0-12a3671cc141
relation.isAuthorOfPublication5904d222-2a67-4e8f-b3a4-4235079fa385
relation.isAuthorOfPublicationfac74470-b00f-48d5-b026-6dfbc38b8b39
relation.isAuthorOfPublication0799a9f7-e86f-4bd3-9f8f-e6ea65652a7b
relation.isAuthorOfPublication06831d6f-19bc-4687-8919-dfaa721bfa67
relation.isAuthorOfPublication4459d441-0fc6-4861-8ab8-98e0b5e0452c
relation.isAuthorOfPublication.latestForDiscovery7574dcd5-619b-44d8-9f24-a0358bb965ce
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_DANILOVIC_Potential_role_of_sorafenib_as_neoadjuvant_therapy_in_2018.PDF
Tamanho:
1.27 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - LIM/25
Artigos e Materiais de Revistas Científicas - LIM/28
Artigos e Materiais de Revistas Científicas - LIM/43
Carregar mais